Arcellx - About the company
Arcellx is an acquired company based in Rockville (United States), founded in 2014 by David M Hilbert. It operates as a Developer of T cell-mediated anti tumour therapy. Arcellx has raised $205M in funding from investors like Aju IB Investment, CAM Capital and Samsara BioCapital, with last known valuation of $*****. The company has 3451 active competitors, including 1157 funded and 811 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.
Company Details
Developer of T cell-mediated anti-tumour therapy. The company has developed its proprietary technology ARC-sparX platform used for the treatment of cancer and autoimmune disease. The ARC-T cells are engineered T-cells that bind to sparX proteins and helps to kill diseased cells. The company's products include CART-ddBCMA and ACLX-001 for multiple myeloma and ACLX-002 for AML. It is also developing therapeutics for solid tumours.
- Website
- arcellx.com
- Social
- Email ID
- *****@arcellx.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2014
Location
Rockville, United States
Stage
Acquired
Total Funding
$205M in 5 rounds
Latest Funding Round
Last Known Valuation
$***** as on Feb 23, 2026
Investors
Ranked
335th among 3451 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2025
Employee Count
138 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Gilead (Feb 23, 2026)
Legal entities associated with Arcellx
Arcellx is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Arcellx, Inc. CIN: 1786205 , United States, Active | Dec 17, 2014 | $10M - $50M (As on Dec 31, 2025) | 161 (As on Dec 31, 2024) | - |
Arcellx's acquisition details
Arcellx got acquired by Gilead on Feb 23, 2026.
Click here to take a look at Arcellx's acquisition in detail
Sign up to download Arcellx's company profile
Arcellx's funding and investors
Arcellx has raised a total funding of $205M over 5 rounds. Its first funding round was on Sep 2017. Arcellx has 25 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Arcellx:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 26, 2023 | 9985850 | Post IPO | 4604736 | 9336986 | 6280810 | 1106491 |
Feb 27, 2022 | 5155042 | Post IPO | 3162181 | 2777355 | 6875882 | 1953777 |
Mar 26, 2021 | 6577070 | Series C | 4367873 | 9922825 |
Access funding benchmarks and valuations. Sign up today!View details of Arcellx's funding rounds and investors
Arcellx's founders and board of directors
Founder? Claim ProfileThe founders of Arcellx is David M Hilbert. David M Hilbert and Rami Elghandour are the CEOs of Arcellx.
Here are the details of Arcellx's key team members:
- David M Hilbert: Founder & Co-CEO of Arcellx.
- Rami Elghandour: Co-CEO of Arcellx.
View details of Arcellx's Founder profiles and Board Members
Arcellx's employee count trend
Arcellx has 138 employees as of Sep 26. Here is Arcellx's employee count trend over the years:
Uncover Arcellx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Arcellx's Competitors and alternates
Top competitors of Arcellx include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Arcellx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
6th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
10th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
335th |  Arcellx 2014, Rockville (United States), Acquired | Developer of T cell-mediated anti tumour therapy | $205M | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Arcellx's competitors? Click here to see the top ones
Arcellx's Investments and acquisitions
Arcellx has made no investments or acquisitions yet.
Reports related to Arcellx
Here is the latest report on Arcellx's sector:
News related to Arcellx
Filter this listMedia has covered Arcellx for a total of 29 events in the last 1 year, 12 of them have been about company updates and 1 about partnerships.
•
Gilead Sciences Shares Acquired by AE Wealth Management LLCMarketBeat•Apr 19, 2026•AE Wealth Management, Gilead, Ticino Wealth, Arcellx and 3 others
•
https://www.stocktitan.net/news/GILD/gilead-receives-all-required-regulatory-approvals-for-the-yrnw1hum26x9.htmlStocktitan•Apr 17, 2026•Arcellx, Gilead
•
Gilead Sciences Nears $2B Acquisition of Ouro MedicinesThemiddlemarket•Mar 23, 2026•Ouro Medicines, Gilead, Arcellx, Galapagos and 1 other
•
Gilead Sciences to Acquire Arcellx for $7.8 BillionFinancial Times•Feb 23, 2026•Arcellx, Gilead, Ademi, AXQ Capital and 13 others
•
Monaco Asset Management SAM Acquires 78,589 Shares of Arcellx (ACLX)MarketBeat•Feb 21, 2026•Monaco Asset Management, Arcellx, Gilead
•
Gilead Acquires Cancer Drug from China-Based Genhouse for $80M UpfrontEndpoints•Feb 14, 2026•Gilead, Ashton Thomas Private Wealth, AGF Management Limited, SEB and 6 others
•
•
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple MyelomaBusiness Wire•Dec 07, 2025•Arcellx
•
RenaissanceRe Holdings Ltd. $RNR Shares Sold by Intech Investment Management LLCMarketBeat•Nov 17, 2025•Intech, RenaissanceRe, Tyson Foods, Dick's Sporting Goods and 54 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Arcellx
Explore our recently published companies
- Mood Packaging Studio (Brand Consulting Srl) - Italy based, 2016 founded, Unfunded company
- Fieldoor - Japan based, Unfunded company
- Notify Buddy - Unfunded company
- Suzanne Odell - San Francisco based, Unfunded company
- NRFeedmill - Unfunded company
- Grand Ferdinand - Unfunded company
